These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31921963)

  • 1. Alzheimer's Prevention Initiative Generation Program: Development of an
    Langlois CM; Bradbury A; Wood EM; Roberts JS; Kim SYH; Riviere ME; Liu F; Reiman EM; Tariot PN; Karlawish J; Langbaum JB
    Alzheimers Dement (N Y); 2019; 5():705-716. PubMed ID: 31921963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
    Lopez Lopez C; Tariot PN; Caputo A; Langbaum JB; Liu F; Riviere ME; Langlois C; Rouzade-Dominguez ML; Zalesak M; Hendrix S; Thomas RG; Viglietta V; Lenz R; Ryan JM; Graf A; Reiman EM
    Alzheimers Dement (N Y); 2019; 5():216-227. PubMed ID: 31211217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.
    Cassidy MR; Roberts JS; Bird TD; Steinbart EJ; Cupples LA; Chen CA; Linnenbringer E; Green RC
    Alzheimers Dement; 2008 Nov; 4(6):406-13. PubMed ID: 19012865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.
    Bemelmans SA; Tromp K; Bunnik EM; Milne RJ; Badger S; Brayne C; Schermer MH; Richard E
    Alzheimers Res Ther; 2016 Nov; 8(1):46. PubMed ID: 27832826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting recall of different types of personal genetic information about Alzheimer's disease risk: the REVEAL study.
    Besser AG; Sanderson SC; Roberts JS; Chen CA; Christensen KD; Lautenbach DM; Cupples LA; Green RC
    Public Health Genomics; 2015; 18(2):78-86. PubMed ID: 25634646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease.
    Relkin NR; Kwon YJ; Tsai J; Gandy S
    Ann N Y Acad Sci; 1996 Dec; 802():149-76. PubMed ID: 8993494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics.
    Roberts JS; Christensen KD; Green RC
    Clin Genet; 2011 Nov; 80(5):407-14. PubMed ID: 21696382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol.
    Bocchetta M; Mega A; Bernardi L; Di Maria E; Benussi L; Binetti G; Borroni B; Colao R; Di Fede G; Fostinelli S; Galimberti D; Gennarelli M; Ghidoni R; Piaceri I; Pievani M; Porteri C; Redaelli V; Rossi G; Suardi S; Babiloni C; Scarpini E; Tagliavini F; Padovani A; Nacmias B; Sorbi S; Frisoni GB; Bruni AC;
    J Alzheimers Dis; 2016; 51(1):277-91. PubMed ID: 26901402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOE Genotype Disclosure Influences Decisions About Future Planning but not Adoption of Healthy Lifestyle Changes in Cognitively Unimpaired Individuals.
    Popescu DL; Lee AK; Arthur E; Thompson LI; Alber J
    J Geriatr Psychiatry Neurol; 2024 Nov; 37(6):482-495. PubMed ID: 38459948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disclosure of Genetic Risk Factors for Alzheimer's Disease to Cognitively Healthy Individuals-From Current Practice towards a Personalised Medicine Scenario.
    Galluzzi S; Pievani M; Zanetti O; Benussi L; The Italian-DIAfN Working Group ; Frisoni GB; Di Maria E
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Alzheimer's Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer's Disease.
    Lopez Lopez C; Caputo A; Liu F; Riviere ME; Rouzade-Dominguez ML; Thomas RG; Langbaum JB; Lenz R; Reiman EM; Graf A; Tariot PN
    J Prev Alzheimers Dis; 2017; 4(4):242-246. PubMed ID: 29181489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results.
    Moreno-Grau S; Rodríguez-Gómez O; Sanabria Á; Pérez-Cordón A; Sánchez-Ruiz D; Abdelnour C; Valero S; Hernández I; Rosende-Roca M; Mauleón A; Vargas L; Lafuente A; Gil S; Santos-Santos MÁ; Alegret M; Espinosa A; Ortega G; Guitart M; Gailhajanet A; de Rojas I; Sotolongo-Grau Ó; Ruiz S; Aguilera N; Papasey J; Martín E; Peleja E; ; Lomeña F; Campos F; Vivas A; Gómez-Chiari M; Tejero MÁ; Giménez J; Serrano-Ríos M; Orellana A; Tárraga L; Ruiz A; Boada M;
    Alzheimers Dement; 2018 May; 14(5):634-643. PubMed ID: 29156223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of genetic test disclosure and genetic counseling in a large Parkinson's disease research study.
    Verbrugge J; Cook L; Miller M; Rumbaugh M; Schulze J; Heathers L; Wetherill L; Foroud T
    J Genet Couns; 2021 Jun; 30(3):755-765. PubMed ID: 33319432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.
    Jicha GA; Abner EL; Arnold SE; Carrillo MC; Dodge HH; Edland SD; Fargo KN; Feldman HH; Goldstein LB; Hendrix J; Peters R; Robillard JM; Schneider LS; Titiner JR; Weber CJ;
    Alzheimers Dement; 2022 Jun; 18(6):1109-1118. PubMed ID: 34590417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.
    Ketchum FB; Chin NA; Grill J; Gleason CE; Erickson C; Clark LR; Paulsen JS; Kind AJH
    Alzheimers Dement; 2022 Oct; 18(10):1969-1979. PubMed ID: 35213786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention.
    Schipper HM
    Alzheimers Dement; 2011 Jul; 7(4):e118-23. PubMed ID: 21665554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the personal utility of Alzheimer's disease-related biomarker testing in the research context.
    Bunnik EM; Richard E; Milne R; Schermer MHN
    J Med Ethics; 2018 Dec; 44(12):830-834. PubMed ID: 30154216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study.
    Cupples LA; Farrer LA; Sadovnick AD; Relkin N; Whitehouse P; Green RC
    Genet Med; 2004; 6(4):192-6. PubMed ID: 15266206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Application of APOE in Alzheimer's Prevention: A Precision Medicine Approach.
    Berkowitz CL; Mosconi L; Rahman A; Scheyer O; Hristov H; Isaacson RS
    J Prev Alzheimers Dis; 2018; 5(4):245-252. PubMed ID: 30298183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.